Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.

Ann Hematol 2018 Feb 12;97(2):267-276. Epub 2017 Nov 12.

Clinic of Hematology, Clinical Center of Serbia, 2 Koste Todorovica Str, Belgrade, 11000, Serbia.

The prognostic value of the International Prognostic Index (IPI) has been re-evaluated in the rituximab-treated diffuse large B cell lymphoma (DLBCL) patients. Accordingly, National Comprehensive Cancer Network-IPI (NCCN-IPI) has been introduced to estimate prognosis of DLBCL patients. However, comorbidities that frequently affect elderly DLBCL patients were not analyzed. The aim of this study was to evaluate the prognostic significance of comorbidities using Charlson Comorbidity Index (CCI) in 962 DLBCL patients. According to CCI, majority of patients (73.6%) did not have any comorbidity, while high CCI (≥ 2) was observed in 71/962 (7.4%) patients, and in 55/426 (12.9%) of the elderly patients aged ≥ 60 years. When the CCI was analyzed in a multivariate model along with the NCCN-IPI parameters, it stood out as a threefold independent risk factor of a lethal outcome. Also, we have developed a novel comorbidity-NCCN-IPI (cNCCN-IPI) by adding additional 3 points if the patient had a CCI ≥ 2. Four risk groups emerged with the following patient distribution in low, low-intermediate, high-intermediate, and high group: 3.4, 34.3, 49.4, and 12.5%, respectively. The prognostic value of the new cNCCN-IPI was 2.1% improved compared to that of the IPI, and 1.3% improved compared to that of the NCCN-IPI (p < 0.05). This difference was more pronounced in elderly patients, in whom the cNCCN-IPI showed a 5.1% better discriminative power compared to that of the IPI, and 3.6% better compared to the NCCN-IPI. The NCCN-IPI enhanced by the CCI and combined with redistributed risk groups is better for differentiating risk categories in unselected DLBCL patients, especially in the elderly.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3170-zDOI Listing
February 2018
52 Reads

Publication Analysis

Top Keywords

dlbcl patients
16
diffuse large
8
cci ≥ 2
8
large cell
8
improved compared
8
prognostic significance
8
significance comorbidities
8
patients
8
prognostic
5
cci
5
high-intermediate high
4
high group
4
≥ 2 observed
4
71/962 74%
4
observed 71/962
4
patients 55/426
4
elderly patients
4
low low-intermediate
4
129% elderly
4
55/426 129%
4

References

(Supplied by CrossRef)

LH Sehn et al.
Blood 2007

M Ziepert et al.
J Clin Oncol 2010

Z Zhou et al.
Blood 2014

C Montalbán et al.
Br J Haematol 2017

HS Hwang et al.
Ann Hematol 2016

KT Prochazka et al.
Br J Cancer 2016

BK Link et al.
Leuk Lymphoma 2011

B Coiffier et al.
Blood 2010

M Pfreundschuh et al.
Lancet Oncol 2011

TM Habermann et al.
J Clin Oncol 2006

Similar Publications